Friday, September 21, 2012

New Phase 2b Trial of Tirasemtiv (CK-2017357) in ALS

Article Highlights:

  • A new phase 2b clinical trial of tirasemtiv (formerly CK-2017357) in people with amyotrophic lateral sclerosis (ALS) is set to launch in late 2012.

  • The new phase trial is designed to evaluate the safety, tolerability and efficacy (how well the therapy works) of tirasemtiv in people with ALS.

  • Investigators will measure trial participants’ images musclepulmonary, respiratory and skeletal muscle function.

  • Tirasemtiv is thought to increase the sensitivity of muscle fibers to calcium, resulting in a potential increase in muscle force generation.

See more info here

No comments:

Post a Comment